Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

With growth from Yeztugo, Gilead stock could be a steal. Should you invest $1,000 in Gilead Sciences right now? Before you buy stock in Gilead Sciences, consider this: ...

Without Yeztugo, that's already a great price. With growth from Yeztugo, Gilead stock could be a steal. Should you invest $1,000 in Gilead Sciences right now?

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead Sciences is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top cheap pharmaceutical stocks to buy now. Morgan Stanley analyst Terence ...

Gilead Sciences has secured approval from the United States health authorities for its new HIV prevention injection, Yeztugo, but concerns are growing over its steep price tag.

Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV ...